55.43
price down icon0.02%   -0.010
after-market Dopo l'orario di chiusura: 55.30 -0.13 -0.23%
loading
Precedente Chiudi:
$55.44
Aprire:
$56.45
Volume 24 ore:
1.13M
Relative Volume:
0.71
Capitalizzazione di mercato:
$5.36B
Reddito:
$4.10M
Utile/perdita netta:
$-568.53M
Rapporto P/E:
-8.9233
EPS:
-6.2118
Flusso di cassa netto:
$-401.18M
1 W Prestazione:
+2.21%
1M Prestazione:
-2.62%
6M Prestazione:
+11.96%
1 anno Prestazione:
-23.88%
Intervallo 1D:
Value
$54.09
$57.58
Intervallo di 1 settimana:
Value
$52.90
$57.58
Portata 52W:
Value
$44.12
$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Nome
Crispr Therapeutics Ag
Name
Telefono
(617) 315-4600
Name
Indirizzo
BAARERSTRASSE 14, ZUG
Name
Dipendente
393
Name
Cinguettio
@crisprtx
Name
Prossima data di guadagno
2026-11-09
Name
Ultimi documenti SEC
Name
CRSP's Discussions on Twitter

Compare CRSP vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CRSP icon
CRSP
Crispr Therapeutics Ag
55.43 5.24B 4.10M -568.53M -401.18M -6.2118
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
504.73 133.37B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
190.01 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
735.20 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.21 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
206.64 43.93B 742.00K -1.37B -1.07B -7.0731

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-18 Iniziato JP Morgan Overweight
2025-02-14 Aggiornamento Evercore ISI In-line → Outperform
2025-02-12 Aggiornamento TD Cowen Sell → Hold
2025-02-03 Iniziato H.C. Wainwright Buy
2024-08-06 Reiterato Needham Buy
2024-08-02 Iniziato Rodman & Renshaw Buy
2024-06-28 Ripresa Guggenheim Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-11 Downgrade TD Cowen Market Perform → Underperform
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-27 Iniziato Mizuho Buy
2023-08-17 Aggiornamento Citigroup Neutral → Buy
2023-05-30 Iniziato William Blair Outperform
2023-04-13 Iniziato Cantor Fitzgerald Overweight
2023-03-21 Iniziato Bernstein Mkt Perform
2023-03-17 Iniziato Bryan Garnier Buy
2023-03-07 Iniziato Robert W. Baird Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-08-09 Downgrade Barclays Overweight → Equal Weight
2022-06-23 Downgrade Evercore ISI Outperform → In-line
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-04-28 Iniziato Credit Suisse Neutral
2021-12-07 Iniziato Cowen Market Perform
2021-10-19 Iniziato SVB Leerink Outperform
2021-06-14 Aggiornamento Citigroup Sell → Neutral
2021-04-21 Aggiornamento Jefferies Hold → Buy
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-10 Reiterato Chardan Capital Markets Buy
2020-12-10 Downgrade Jefferies Buy → Hold
2020-12-10 Reiterato Needham Buy
2020-12-07 Downgrade Wells Fargo Overweight → Equal Weight
2020-10-23 Iniziato RBC Capital Mkts Sector Perform
2020-10-05 Iniziato BofA Securities Buy
2020-07-28 Reiterato Needham Buy
2020-07-14 Iniziato SunTrust Buy
2020-06-15 Reiterato Canaccord Genuity Buy
2020-03-05 Iniziato Stifel Hold
2020-02-03 Downgrade Evercore ISI Outperform → In-line
2019-11-19 Aggiornamento William Blair Mkt Perform → Outperform
2019-11-12 Aggiornamento Oppenheimer Perform → Outperform
2019-08-01 Iniziato Jefferies Buy
2019-07-26 Iniziato Canaccord Genuity Buy
2019-06-10 Iniziato ROTH Capital Buy
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-14 Iniziato William Blair Mkt Perform
2019-01-28 Downgrade Goldman Buy → Neutral
2019-01-22 Downgrade Citigroup Neutral → Sell
Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

pulisher
Oct 01, 2026

CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Sep 30, 2026

CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - uk.finance.yahoo.com

Sep 30, 2026
pulisher
Sep 30, 2026

Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. - Yahoo Finance

Sep 30, 2026
pulisher
Sep 30, 2026

CRISPR Therapeutics AG (CRSP) Stock forecasts - Yahoo Finance Singapore

Sep 30, 2026
pulisher
Sep 29, 2026

Total common shares outstanding of CRISPR Therapeutics AG – HAN:1CG - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - The Motley Fool

Sep 29, 2026
pulisher
Sep 28, 2026

CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com

Sep 28, 2026
pulisher
Sep 27, 2026

One CRISPR treatment cut “bad” cholesterol in half for a full year - ScienceDaily

Sep 27, 2026
pulisher
Sep 27, 2026

Form 144 CRISPR THERAPEUTICS AG For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026
pulisher
Sep 26, 2026

Crispr Therapeutics AG (CRSP) Stock Price Today: $54.23 - Pluang

Sep 26, 2026
pulisher
Sep 26, 2026

CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - Stocktwits

Sep 26, 2026
pulisher
Sep 25, 2026

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Sep 25, 2026
pulisher
Sep 25, 2026

CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com

Sep 25, 2026
pulisher
Sep 24, 2026

Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Canada

Sep 24, 2026
pulisher
Sep 24, 2026

Form 4 CRISPR Therapeutics AG For: 24 September - Investing.com India

Sep 24, 2026
pulisher
Sep 24, 2026

CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media

Sep 24, 2026
pulisher
Sep 24, 2026

CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat

Sep 24, 2026
pulisher
Sep 24, 2026

CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang

Sep 24, 2026
pulisher
Sep 24, 2026

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha

Sep 24, 2026
pulisher
Sep 24, 2026

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Sep 24, 2026
pulisher
Sep 23, 2026

CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

CRISPR Therapeutics stock trades below targets despite approved gene therapy; analyst sees 85% upside potential. - Pluang

Sep 23, 2026
pulisher
Sep 23, 2026

CRISPR Therapeutics AG (CRSP) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire

Sep 23, 2026
pulisher
Sep 23, 2026

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - uk.finance.yahoo.com

Sep 23, 2026
pulisher
Sep 23, 2026

What Put the CRISPR Therapeutics (CRSP) Story on the Radar? - Kalkine Media

Sep 23, 2026
pulisher
Sep 22, 2026

CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale - Stock Titan

Sep 22, 2026
pulisher
Sep 22, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 22, 2026
pulisher
Sep 21, 2026

Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat

Sep 21, 2026
pulisher
Sep 21, 2026

CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 - Stock Titan

Sep 21, 2026
pulisher
Sep 21, 2026

Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution - Stock Titan

Sep 21, 2026
pulisher
Sep 20, 2026

Why CRISPR Therapeutics (CRSP) Is Back In The Spotlight - simplywall.st

Sep 20, 2026
pulisher
Sep 20, 2026

New Treatment Cuts “Bad” Cholesterol in Half for a Full Year - SciTechDaily

Sep 20, 2026
pulisher
Sep 20, 2026

CRISPR Therapeutics stock edges lower as investors digest latest pipeline and earnings figures - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 20, 2026

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 - The Motley Fool

Sep 20, 2026
pulisher
Sep 18, 2026

Crispr Therapeutics' Diverse Gene Editing Portfolio Supports Positive Long-Term Outlook - Morningstar

Sep 18, 2026
pulisher
Sep 18, 2026

CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo Finance

Sep 18, 2026
pulisher
Sep 18, 2026

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - TradingView

Sep 18, 2026
pulisher
Sep 18, 2026

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? - The Motley Fool

Sep 18, 2026
pulisher
Sep 17, 2026

CRISPR Therapeutics (NASDAQ:CRSP): What's Behind Its Stock Surge? - Kalkine Media

Sep 17, 2026
pulisher
Sep 17, 2026

Director at CRISPR Therapeutics (NASDAQ: CRSP) files notice for six-figure stock sale - Stock Titan

Sep 17, 2026
pulisher
Sep 17, 2026

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.6%What's Next? - MarketBeat

Sep 17, 2026
pulisher
Sep 17, 2026

CRISPR Therapeutics Surges 11.39% as CRSP Stock Breaks Above $58RSI Oversold Picks - careplusvn.com

Sep 17, 2026
pulisher
Sep 17, 2026

Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? - Yahoo Finance

Sep 17, 2026

Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Crispr Therapeutics Ag Azioni (CRSP) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
KASINGER JAMES R.
General Counsel and Secretary
Sep 22 '26
Sale
60.24
10,400
626,460
94,784
$96.90
price up icon 0.05%
$57.16
price down icon 0.82%
$35.72
price up icon 0.62%
$219.72
price down icon 4.96%
ONC ONC
$358.07
price down icon 0.20%
$206.64
price up icon 0.36%
Capitalizzazione:     |  Volume (24 ore):